AEON BIOPHARMA INC (AEON) Fundamental Analysis & Valuation

NYSEARCA:AEON • US00791X2099

Current stock price

1.1499 USD
+0.01 (+0.87%)
Last:

This AEON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AEON Profitability Analysis

1.1 Basic Checks

  • In the past year AEON has reported negative net income.
  • In the past year AEON has reported a negative cash flow from operations.
  • AEON had negative earnings in 4 of the past 5 years.
  • AEON had a negative operating cash flow in each of the past 5 years.
AEON Yearly Net Income VS EBIT VS OCF VS FCFAEON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -14.03%
ROE N/A
ROIC N/A
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEON Yearly ROA, ROE, ROICAEON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AEON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEON Yearly Profit, Operating, Gross MarginsAEON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 2K 4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. AEON Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for AEON has been increased compared to 1 year ago.
  • AEON has less shares outstanding than it did 5 years ago.
  • AEON has a worse debt/assets ratio than last year.
AEON Yearly Shares OutstandingAEON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
AEON Yearly Total Debt VS Total AssetsAEON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • AEON has an Altman-Z score of -53.63. This is a bad value and indicates that AEON is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.63
ROIC/WACCN/A
WACCN/A
AEON Yearly LT Debt VS Equity VS FCFAEON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

2.3 Liquidity

  • AEON has a Current Ratio of 1.12. This is a normal value and indicates that AEON is financially healthy and should not expect problems in meeting its short term obligations.
  • AEON has a Quick Ratio of 1.12. This is a normal value and indicates that AEON is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
AEON Yearly Current Assets VS Current LiabilitesAEON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AEON Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.01% over the past year.
  • The Earnings Per Share has been growing by 56.13% on average over the past years. This is a very strong growth
EPS 1Y (TTM)99.01%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%95.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AEON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -49.88% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-101.18%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 50M 100M 150M 200M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 40 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. AEON Valuation Analysis

4.1 Price/Earnings Ratio

  • AEON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year AEON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEON Price Earnings VS Forward Price EarningsAEON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEON Per share dataAEON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

  • AEON's earnings are expected to decrease with -26.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AEON Dividend Analysis

5.1 Amount

  • No dividends for AEON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AEON Fundamentals: All Metrics, Ratios and Statistics

AEON BIOPHARMA INC

NYSEARCA:AEON (3/17/2026, 9:37:16 AM)

1.1499

+0.01 (+0.87%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-14
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner Change79.05%
Ins OwnersN/A
Ins Owner Change27.36%
Market Cap42.73M
Revenue(TTM)N/A
Net Income(TTM)-1.64M
Analysts82.5
Price Target5.3 (360.91%)
Short Float %1.92%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.98
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS-0.43
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1589.97%
ROA(5y)-1126.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -53.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.01%
EPS 3YN/A
EPS 5Y56.13%
EPS Q2Q%95.6%
EPS Next Y-101.18%
EPS Next 2Y-41.9%
EPS Next 3Y-26.16%
EPS Next 5Y-49.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-110.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.99%
OCF growth 3YN/A
OCF growth 5YN/A

AEON BIOPHARMA INC / AEON Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AEON BIOPHARMA INC?

ChartMill assigns a fundamental rating of 1 / 10 to AEON.


What is the valuation status of AEON BIOPHARMA INC (AEON) stock?

ChartMill assigns a valuation rating of 0 / 10 to AEON BIOPHARMA INC (AEON). This can be considered as Overvalued.


What is the profitability of AEON stock?

AEON BIOPHARMA INC (AEON) has a profitability rating of 0 / 10.